These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6085339)

  • 41. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
    Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Tumor markers in breast cancer].
    Polevaia EB; Tkacheva GA; Letiagin VP; Ivanov VM; Koposova TL
    Sov Med; 1985; (3):25-9. PubMed ID: 4023831
    [No Abstract]   [Full Text] [Related]  

  • 43. Tumor markers carcinoembryonic antigen, tissue polypeptide antigen, and carbohydrate antigen 19/9 in liver diseases.
    Putzki H; Ledwoch J; Student A; Jablonski M; Heymann H
    J Surg Oncol; 1988 Feb; 37(2):133-5. PubMed ID: 3278167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER].
    Buda F; Aragona P; Giani G; Sisto R; Di Nardo G; Binotto F; Gangemi P; De Zerbi T; Gentile G; Papadia A
    G Ital Oncol; 1989; 9(2-3):67-72. PubMed ID: 2767730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
    Silver HK; Archibald BL; Ragaz J; Coldman AJ
    Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
    Putzki H; Reichert B; Jablonski M; Heymann H
    Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The tumor markers TPA and CEA in the after care of breast cancer].
    Beaufort F; Fueger GF; Steiner H
    Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].
    Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L
    Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Mucoid carcinoma antigen--a new tumor marker].
    Bieglmayer C; Szepesi T; Neunteufel W
    Gynakol Rundsch; 1988; 28 Suppl 2():203-5. PubMed ID: 3234919
    [No Abstract]   [Full Text] [Related]  

  • 52. Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance.
    Lüthgens M; Schlegel G
    Cancer Detect Prev; 1983; 6(1-2):51-9. PubMed ID: 6883393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue polypeptide antigen and cancer antigen 125 in pregnancy--these two cancer-related antigens are oncoplacental?
    Inaba N; Fukazawa I; Ota Y; Nito A; Ijichi M; Sato T; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Oct; 37(10):2139-40. PubMed ID: 3908588
    [No Abstract]   [Full Text] [Related]  

  • 54. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
    Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
    Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [SCC-antigen in patients with lung cancer].
    Matsubara Y; Yasuda Y; Hanawa T; Miyamoto Y; Ninomiya K; Hatakenaka R; Funatsu T; Ikeda S
    Nihon Gan Chiryo Gakkai Shi; 1986 Jun; 21(5):1036-48. PubMed ID: 3760648
    [No Abstract]   [Full Text] [Related]  

  • 57. [Distribution and prognostic value of CEA and TPA in cancer of the lung].
    Leonardo E; Dogliotti C; Mancuso M; Sanfilippo B; Oliaro A
    Minerva Med; 1986 Mar; 77(11):375-9. PubMed ID: 3703330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Diagnostic predictability of CEA and TPA tumor markers in bronchoalveolar lavage fluid].
    Loos U; Oehr P; Genske F; Schlack W
    Prax Klin Pneumol; 1988 Jun; 42 Suppl 1():235-7. PubMed ID: 3174571
    [No Abstract]   [Full Text] [Related]  

  • 60. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.